文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

系统性红斑狼疮弥漫性肺泡出血病死率的危险因素:系统评价和荟萃分析。

Risk factors for mortality of diffuse alveolar hemorrhage in systemic lupus erythematosus: a systematic review and meta-analysis.

机构信息

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, The Ministry of Education Key Laboratory, Beijing, 100730, China.

Clinical Immunology Centre, Medical Epigenetics Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, The Ministry of Education Key Laboratory, Beijing, 100730, China.

出版信息

Arthritis Res Ther. 2021 Feb 16;23(1):57. doi: 10.1186/s13075-021-02435-9.


DOI:10.1186/s13075-021-02435-9
PMID:33593433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7885396/
Abstract

BACKGROUND: Diffuse alveolar hemorrhage (DAH) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). The current knowledge of the prognostic factors for SLE-associated DAH is controversial. This meta-analysis was undertaken to investigate the relevant risk factors for mortality in SLE-associated DAH. METHODS: Studies were searched from PubMed, EMBASE, and Web of Science databases published up to May 27, 2020, and were selected or removed according to the inclusion and exclusion criteria. Two reviewers extracted data independently from the enrolled studies, and the odds ratios (OR) or the standardized mean difference (SMD) was utilized to identify and describe the prognostic factors for mortality. RESULTS: Eight studies encompassing 251 patients with SLE-associated DAH were included in the meta-analysis. No significant publication bias was shown. Age at the diagnosis of DAH (SMD = 0.35, 95% confidence interval (CI) (0.08, 0.61), P = 0.01, I = 0.0%) was found to be an independent risk factor of mortality. Longer lupus disease duration (SMD = 0.28, 95% CI (0.01, 0.55), P = 0.042, I = 0.0%), concurrent infection (OR = 2.77, 95% CI (1.55, 4.95), P = 0.001, I = 37.5%), plasmapheresis treatment (OR = 1.96, 95% CI (1.04, 3.70), P = 0.038, I = 14.6%), and mechanical ventilation (OR = 6.11, 95% CI (3.27, 11.39), P < 0.0001, I = 23.3%) were also related to poor survival, whereas no noticeable relationships were revealed between survival and concurrent lupus nephritis (OR = 5.45, 95% CI (0.52, 56.95), P = 0.16, I = 58.4%) or treatment of cyclophosphamide (CTX) (OR = 0.74, 95% CI (0.16, 3.41), P = 0.70, I = 75.5%). CONCLUSIONS: Older age at the diagnosis of DAH, longer disease duration of SLE, concurrent infection, plasmapheresis treatment, and mechanical ventilation were found related to increased mortality in patients with SLE-associated DAH according to our meta-analysis. However, due to limited studies with heterogeneity, these results should be interpreted cautiously. Notably, severe diseases rendered the requirement of plasmapheresis treatment and mechanical ventilation are themselves associated with poor outcome. Randomized trials of therapeutics are needed to determine the most efficacious strategies for SLE-associated DAH for better management of this life-threatening complication.

摘要

背景:弥漫性肺泡出血(DAH)是系统性红斑狼疮(SLE)的一种罕见但危及生命的并发症。目前,SLE 相关 DAH 的预后因素的相关知识存在争议。本荟萃分析旨在研究 SLE 相关 DAH 患者死亡的相关危险因素。

方法:检索了截至 2020 年 5 月 27 日,PubMed、EMBASE 和 Web of Science 数据库中发表的研究,并根据纳入和排除标准进行选择或排除。两名评审员从纳入的研究中独立提取数据,并使用优势比(OR)或标准化均数差(SMD)来识别和描述与死亡率相关的预后因素。

结果:荟萃分析纳入了 8 项共 251 例 SLE 相关 DAH 患者的研究。未发现明显的发表偏倚。DAH 诊断时的年龄(SMD=0.35,95%置信区间(CI)(0.08,0.61),P=0.01,I=0.0%)是死亡率的独立危险因素。SLE 疾病持续时间较长(SMD=0.28,95%CI(0.01,0.55),P=0.042,I=0.0%)、合并感染(OR=2.77,95%CI(1.55,4.95),P=0.001,I=37.5%)、血浆置换治疗(OR=1.96,95%CI(1.04,3.70),P=0.038,I=14.6%)和机械通气(OR=6.11,95%CI(3.27,11.39),P<0.0001,I=23.3%)与预后不良相关,而合并狼疮性肾炎(OR=5.45,95%CI(0.52,56.95),P=0.16,I=58.4%)或环磷酰胺(CTX)治疗(OR=0.74,95%CI(0.16,3.41),P=0.70,I=75.5%)与生存率之间无明显关系。

结论:根据我们的荟萃分析,DAH 诊断时年龄较大、SLE 疾病持续时间较长、合并感染、血浆置换治疗和机械通气与 SLE 相关 DAH 患者死亡率增加相关。然而,由于存在异质性的研究有限,这些结果应谨慎解释。值得注意的是,严重疾病导致需要血浆置换治疗和机械通气本身与不良预后相关。需要随机临床试验来确定 SLE 相关 DAH 的最有效治疗策略,以更好地管理这种危及生命的并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/1d6ffb1086ea/13075_2021_2435_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/75944f6fa2f4/13075_2021_2435_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/bbf758f69e51/13075_2021_2435_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/3b0d34cbf106/13075_2021_2435_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/1d6ffb1086ea/13075_2021_2435_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/75944f6fa2f4/13075_2021_2435_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/bbf758f69e51/13075_2021_2435_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/3b0d34cbf106/13075_2021_2435_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8f5/7885396/1d6ffb1086ea/13075_2021_2435_Fig4_HTML.jpg

相似文献

[1]
Risk factors for mortality of diffuse alveolar hemorrhage in systemic lupus erythematosus: a systematic review and meta-analysis.

Arthritis Res Ther. 2021-2-16

[2]
Clinical Characteristics and Risk Factors of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis Based on Observational Studies.

Clin Rev Allergy Immunol. 2020-12

[3]
Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome.

Medicine (Baltimore). 1997-5

[4]
Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China.

Lupus. 2020-6

[5]
Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a potential key to improve outcomes.

Clin Rheumatol. 2023-6

[6]
Diffuse alveolar hemorrhage in systemic lupus erythematosus: risk factors and clinical outcome: results from affiliated hospitals of Catholic University of Korea.

Lupus. 2010-10-18

[7]
Diffuse alveolar hemorrhage in Colombian patients with systemic lupus erythematosus.

Clin Rheumatol. 2007-11

[8]
Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER).

Rheumatol Int. 2024-11

[9]
Systematic Review of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Focus on Outcome and Therapy.

J Clin Rheumatol. 2015-9

[10]
Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus.

Semin Arthritis Rheum. 2017-6

引用本文的文献

[1]
Characteristics of Systemic Lupus Erythematosus Patients with Diffuse Alveolar Hemorrhage: Clinical Features and Outcomes from a Single-Center Experience.

J Clin Med. 2025-8-8

[2]
Diffuse Alveolar Hemorrhage as the First Presentation of Systemic Lupus Erythematosus: A Case Report.

Am J Case Rep. 2025-6-21

[3]
Cryptogenic Organizing Pneumonia Is Associated With Increased Mortality Risk in Hospitalizations for Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis.

Cureus. 2024-9-22

[4]
Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER).

Rheumatol Int. 2024-11

[5]
The interplay between rheumatic diseases and pulmonary health.

Rheumatol Int. 2024-7

[6]
Epidemiology of systemic lupus erythematosus in Korea.

J Rheum Dis. 2023-10-1

[7]
A novel PRKDC mutation caused B lymphocytes V(D)J rearrangement disorder in the SLE-DAH like symptoms patient.

Pediatr Rheumatol Online J. 2023-8-14

[8]
Hollow-polydopamine-nanocarrier-based near-infrared-light/pH-responsive drug delivery system for diffuse alveolar hemorrhage treatment.

Front Chem. 2023-6-15

[9]
Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a potential key to improve outcomes.

Clin Rheumatol. 2023-6

[10]
Rheumatic diseases associated with alveolar hemorrhage: analysis of the national inpatient sample.

Clin Rheumatol. 2023-4

本文引用的文献

[1]
Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus.

Rheumatology (Oxford). 2020-11-1

[2]
Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China.

Lupus. 2020-6

[3]
Therapeutic Plasma Exchange Using Membrane Plasma Separation.

Clin J Am Soc Nephrol. 2020-9-7

[4]
Diffuse Alveolar Hemorrhage: A Cohort of Patients With Systemic Lupus Erythematosus.

J Clin Rheumatol. 2020-10

[5]
Diffuse Alveolar Hemorrhage in Autoimmune Diseases.

Curr Rheumatol Rep. 2017-5

[6]
Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus.

Semin Arthritis Rheum. 2017-6

[7]
Adverse events in apheresis: An update of the WAA registry data.

Transfus Apher Sci. 2016-2

[8]
Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review.

Autoimmun Rev. 2015-8-28

[9]
Systematic Review of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Focus on Outcome and Therapy.

J Clin Rheumatol. 2015-9

[10]
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Syst Rev. 2015-1-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索